Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KQ-2002 is an autologous, bispecific Chimeric Antigen Receptor (CAR) T-cell therapy designed to target both CD19 and CD22 antigens on B-cell surfaces. This dual-targeting approach is intended to enhance therapeutic efficacy and prevent disease relapse caused by antigen escape, a common mechanism of resistance in single-antigen targeted CAR-T therapies where cancer cells lose expression of the targeted protein (typically CD19). KQ-2002 is manufactured on-site (point-of-care) at specialized facilities and is currently being investigated for the treatment of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on KQ-2002.